Cost-effectiveness Comparison of Ceftazidime/Avibactam Versus Meropenem in the Empirical Treatment of Hospital-acquired Pneumonia, Including Ventilator-associated Pneumonia, in Italy - Tichy, Eszter; Torres, Antoni; Bassetti, Matteo; Kongnakorn, Thitima; Di Virgilio, Roberto; Irani, Paurus; Charbonneau, Claudie (Clinical therapeutics, 2020)
Keywords: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents - economics; Anti-Bacterial Agents - therapeutic use; Antibiotics; avibactam; Azabicyclo Compounds - economics; Azabicyclo Compounds - therapeutic use; CAZ-AVI; Ceftazidime; Ceftazidime - economics; Ceftazidime - therapeutic use; Clinical medicine; Clinical trials; Colistin; Cost analysis; Cost-Benefit Analysis; cost-effective analysis; Double-Blind Method; Drug Combinations; Drug dosages; Drug resistance; E coli; Female; Health care; Healthcare-Associated Pneumonia - drug therapy; Healthcare-Associated Pneumonia - economics; hospital-acquired pneumonia; Hospitals; Human subjects; Humans; Internal Medicine; Italy; Male; Medical Education; Meropenem; Meropenem - economics; Meropenem - therapeutic use; Middle Aged; Mortality; Nosocomial infection; Pathogens; Patients; Pneumonia; Ventilator-associated pneumonia; Ventilators; Young Adult; Italy; United States--US; ventilator-associated pneumonia; cost-effective analysis; ceftazidime; CAZ-AVI; hospital-acquired pneumonia; avibactam